French Biotech SeaBeLife Secures Funding to Combat Liver and Eye Diseases
In a recent pre-Series A funding round, French biotechnology firm SeaBeLife has garnered €2 million to propel its innovative drug research targeted at treating severe liver and eye conditions. Preclinical developments are underway, with clinical trial commencement anticipated in 2026.